Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Thomas R. Einarson, Basil G. Bereza, T. Anders Nielsen, Jan Van Laer & Michiel E. H. Hemels. (2016) Systematic review of models used in economic analyses in moderate-to-severe asthma and COPD. Journal of Medical Economics 19:4, pages 319-355.
Read now
Read now
Thomas R. Einarson, Basil G. Bereza, T. Anders Nielsen & Michiel E. H. Hemels. (2015) Utilities for asthma and COPD according to category of severity: a comprehensive literature review. Journal of Medical Economics 18:7, pages 550-563.
Read now
Read now
Kevin Lock, Koo Wilson, Daniel Murphy & Juan Antonio Riesco. (2011) A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 12:17, pages 2613-2626.
Read now
Read now
Shalini Naik, Khalid M Kamal, Patricia A Keys & Thomas J Mattei. (2010) Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease. ClinicoEconomics and Outcomes Research 2, pages 25-36.
Read now
Read now
Josephine A. Mauskopf, Christine L. Baker, Brigitta U. Monz & Melissa D. Juniper. (2010) Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. Journal of Medical Economics 13:3, pages 403-417.
Read now
Read now
Helen J Starkie, Andrew H Briggs & Mike G Chambers. (2008) Pharmacoeconomics in COPD: lessons for the future. International Journal of Chronic Obstructive Pulmonary Disease 3:1, pages 71-88.
Read now
Read now
Articles from other publishers (16)
Zafar Zafari, Stirling Bryan, Don D. Sin, Tania Conte, Rahman Khakban & Mohsen Sadatsafavi. (2017) A Systematic Review of Health Economics Simulation Models of Chronic Obstructive Pulmonary Disease. Value in Health 20:1, pages 152-162.
Crossref
Crossref
Foruhar Moayeri, Ya-Seng (Arthur) Hsueh, Philip Clarke & David Dunt. (2016) Do Model-Based Studies in Chronic Obstructive Pulmonary Disease Measure Correct Values of Utility? A Meta-Analysis. Value in Health 19:4, pages 363-373.
Crossref
Crossref
Roberto Ravasio. (2015) Cost-Effectiveness Analysis of Long-Acting Bronchodilators for the Treatment of COPD (Moderate to Very Severe). Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2:3, pages GRHTA.5000204.
Crossref
Crossref
Robert Hettle, Hanne Wouters, Jon Ayres, Ray Gani, Steve Kelly, Michaela Lion & Marc Decramer. (2012) Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium. Respiratory Medicine 106:12, pages 1722-1733.
Crossref
Crossref
Jimmy Chong, Charlotta Karner & Phillippa Poole. (2012) Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2016:11.
Crossref
Crossref
Kostas Athanasakis, Michael Igoumenidis, Eleftheria Karampli, Elli Vitsou, Georgia Sykara & John Kyriopoulos. (2012) Cost-Effectiveness of Varenicline Versus Bupropion, Nicotine-Replacement Therapy, and Unaided Cessation in Greece. Clinical Therapeutics 34:8, pages 1803-1814.
Crossref
Crossref
Maureen P.M.H. Rutten-van Mölken & Lucas M.A. Goossens. (2012) Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease. PharmacoEconomics 30:4, pages 271-302.
Crossref
Crossref
O. Zaniolo, S. Iannazzo, L. Pradelli & M. Miravitlles. (2010) Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy. The European Journal of Health Economics 13:1, pages 71-80.
Crossref
Crossref
Gillian M. Keating. (2012) Tiotropium Bromide Inhalation Powder. Drugs 72:2, pages 273-300.
Crossref
Crossref
David Price, Alastair Gray, Rupert Gale, Yumi Asukai, Laura Mungapen, Adam Lloyd, Lars Peters, Katja Neidhardt & Tobias Gantner. (2011) Cost-utility analysis of indacaterol in Germany: A once-daily maintenance bronchodilator for patients with COPD. Respiratory Medicine 105:11, pages 1635-1647.
Crossref
Crossref
Mattias Neyt, Stephan Devriese, Nancy Thiry & Ann Van den Bruel. (2010) Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions. BMC Pulmonary Medicine 10:1.
Crossref
Crossref
Douglas W. Mapel, Michael Schum, Eva Lydick & Jeno P. Marton. (2010) A New Method for Examining the Cost Savings of Reducing COPD Exacerbations. PharmacoEconomics 28:9, pages 733-749.
Crossref
Crossref
Andrew Briggs, Helen Starkie & Olivia Wu. 2009. Asthma and COPD. Asthma and COPD
751
760
.
Andrea M Chen, Suzanne G Bollmeier & Patrick M Finnegan. (2008) Long-Acting Bronchodilator Therapy for the Treatment of Chronic Obstructive Pulmonary Disease. Annals of Pharmacotherapy 42:12, pages 1832-1842.
Crossref
Crossref
Nicholas J. Gross. (2008) Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation. Mayo Clinic Proceedings 83:11, pages 1241-1250.
Crossref
Crossref
Fadia T. Shaya, Du Dongyi, Manabu O. Akazawa, Christopher M. Blanchette, Jingshu Wang, Douglas W. Mapel, Anand Dalal & Steven M. Scharf. (2008) Burden of Concomitant Asthma and COPD in a Medicaid Population*. Chest 134:1, pages 14-19.
Crossref
Crossref